NCT07400588

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

Conditions

• Obese
• Obesity
• Obesity Type 2 Diabetes Mellitus
• Weight Loss

Interventions

Type	Name	Description
DRUG	Aleniglipron	Drug aleniglipron administered orally
DRUG	Placebo	Drug placebo administered orally

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-10-01
• Completion: 2026-11-01
• First posted: 2026-02-10
• Last updated: 2026-02-10

Locations

17 sites across 1 country: United States

Regulatory

• FDA-regulated drug study